C Diff Drug Development

Acurx Pharmaceuticals' (NASDAQ:ACXP) mission in bringing to market an effective and durable treatment for C. difficile was provided a significant step forward. This time, it came as a result of yet another Phase 3

ClinicalTrials.gov identifier: NCT03183141.

Acurx Pharmaceuticals' mission in bringing to market an effective and durable treatment for C. difficile was provided a significant step forward. This time, it came as a result of yet another Phase... | February 8, 2023

Dr. Jessica Allegretti discusses the recent abrupt ending of the CP101 clinical program and why options are important for patients with #Cdiff: https://t.co/zohpEkdELL pic.twitter.com/LHqctmfbA4— HCPLive (@MDMagazine) February 8, 2023

The worldwide Difficile Infections (Clostridium Difficile Associated Disease) Market is predicted to reach a valuation of US$ 809 Million in 2023, with a CAGR of 6% predicted from 2023 to 2033.Clostridium difficile infection (CDI) is a disease caused by toxic compounds produced by the spore-formi...

Acurx Pharmaceuticals CEO David Luci tells Soulstring Media Group why he thinks his company and lead drug candidate, Ibezapolstat, can be a front-line treatment against C. difficile New York, New York--(Newsfile Corp. - February 7, 2023) - Soulstring Media Group, Llc., a market research, aggregator, and digital media production and management company specializing in creating and syndicating content from publicly traded and private companies, announced today that it had published an in-depth inte

Thus far, the phase 2 data on CP101 was generally positive for the treatment of recurrent C difficile infections.

The new report by Stratagem Market Insights titled Global Clostridium Difficile Infection Treatment Market Outlook Report 2022 2030 gives an in depth analysis of the global Clostridium Difficile Infection Treatment market assessing the market based on its segments like Type ...

Dr. Elizabeth Garner speculates the FDA approval of RBX2660 for recurrent C difficile infection will pave the way for more restorative microbiome therapies.

.@VedantaBio is developing oral drugs that are designed to deliver defined bacterial consortia to treat diseases linked to the #microbiome including #CDiff & #IBD. A Phase 3 trial of Vedanta’s VE303 for the treatment of #rCdiff is planned to begin in 2023. https://t.co/Xyew5il3Ba— MTIG (@MTIG_News) January 31, 2023

Happy to share our work in @JAMANetworkOpen In our study patients treated with SER-109 (an oral microbiome therapeutic) had significantly greater improvements in disease-specific HRQOL scores compared with patients treated with placebo through 8 wks #cdiff https://t.co/zL1iUg3LBz pic.twitter.com/77wCrrTIlv— Abhishek Deshpande (@abhishek_dp) January 30, 2023

Infections by Clostridioides difficile , a bacterium that targets the large intestine (colon), impact a significant number of people worldwide. Bacterial colonization is mediated by two exotoxins: toxins A and B. Short peptides that can inhibit the biocatalytic activity of these toxins repres …

Clostridioides difficile infection (CDI) causes intestinal injury. Toxin A and toxin B cause intestinal injury by inducing colonic epithelial cell apoptosis. ADS024 is a Bacillus velezensis strain in development as a single-strain live biotherapeutic product (SS-LBP) to prevent the rec …

Clinical trial setbacks and financial challenges have led Finch Therapeutics to stop a Phase 3 study for its lead microbiome program, a potential treatment for recurrent C. diff infection. As Finch seeks buyers for its remaining assets, the biotech is laying off most of its staff in a corporate restructuring.

The gut microbiome plays a critical but poorly understood role in how drugs work or don't work in the body. It also presents therapeutic possibilities unto itself.

SOMERVILLE, Mass., Jan. 24, 2023 -- Finch Therapeutics Group, Inc. today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection and focus on... | January 24, 2023

.@ServatusLtd's drug development platforms contain engineered proteins for the treatment of autoimmune diseases and live biotherapeutics (LBPs) for the treatment of inflammatory conditions and bacterial infections including #IBD, #CDiff and H. pylori. https://t.co/eUgiukdHkL— MTIG (@MTIG_News) January 23, 2023

In recent years, there has been a growing interest in the use of novel antimicrobial agents able to inhibit or kill food-borne bacteria or to interrupt the onset of food spoilage. Crocus sativus L. petals, typically considered as waste obtained from saffron spice production, could be a source …

Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability.

MELBOURNE, Australia, Jan. 17, 2023 -- Immuron Limited , an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic... | January 17, 2023